Korean J Gastroenterol.  2023 Dec;82(6):313-314. 10.4166/kjg.2023.138.

PAGE-B with Moderate HBV DNA Levels Predicts Risk of Hepatocellular Carcinoma among Patients at Phase Change from Immuno-tolerant Phase to Immune-active Phase in HBeAg-Positive Chronic Hepatitis B

• Lee M

• KMID: 2549817
• DOI: http://doi.org/10.4166/kjg.2023.138

Reference

1. Papatheodoridis G, Dalekos G, Sypsa V, et al. 2016; PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 64:800–806. DOI: 10.1016/j.jhep.2015.11.035. PMID: 26678008.

2. Chun HS, Papatheodoridis GV, Lee M, et al. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B. J Hepatol. 2023; Sep. 19. doi: 10.1016/j.jhep.2023.09.011. DOI: 10.1016/j.jhep.2023.09.011. PMID: 37734683.

3. Liu J, Wang J, Yan X, et al. 2022; Presence of liver inflammation in Asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol Commun. 6:855–866. DOI: 10.1002/hep4.1859. PMID: 34783181. PMCID: PMC8948668.

4. European Association for the Study of the Liver. 2017; EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370–398. DOI: 10.1016/j.jhep.2017.03.021. PMID: 28427875.